LLY
Eli Lilly and Company
LLY has the edge over TCRX overall, supported by stronger fundamentals and lower modeled downside.
TCRX
TScan Therapeutics, Inc.
TCRX trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TCRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
TCRX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TCRX PE Valuation
TCRX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TCRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TCRX on earnings quality, reporting a profit while its opponent remains loss making.
TCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.88 | +$0.23 |
| Q2 2026 | -$0.91 | +$0.17 |
| Q1 2026 | -$0.96 | +$0.12 |
| Q4 2025 | -$1.00 | +$0.14 |
TCRX is still losing money, but far less than before: $0.88 per share over the past year, against $3.01 at its worst in early 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TCRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TCRX on profitability, with a higher operating margin.
TCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $586K | -77% |
| Q2 2026 | $1.1M | -66% |
| Q1 2026 | $982K | -55% |
| Q4 2025 | $2.6M | +286% |
| Q3 2025 | $2.5M | +139% |
| Q2 2025 | $3.1M | +474% |
| Q1 2025 | $2.2M | +284% |
| Q4 2024 | $665K | -91% |
TCRX's revenue has slid since its 2023 peak: $586,000 last quarter, down 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5637% | -4161 points |
| Q2 2026 | -2901% | -1645 points |
| Q1 2026 | -2967% | -1298 points |
| Q4 2025 | -929% | +4591 points |
| Q3 2025 | -1476% | +1634 points |
| Q2 2025 | -1257% | +5108 points |
| Q1 2025 | -1670% | +3873 points |
| Q4 2024 | -5521% | -5224 points |
TCRX's operating margin was −5637% last quarter, down 4161 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TCRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.1M | +$6.8M |
| Q2 2026 | -$28M | +$6.5M |
| Q1 2026 | -$24.3M | +$14.8M |
| Q4 2025 | -$32.2M | -$3.9M |
| Q3 2025 | -$33.9M | -$4.6M |
| Q2 2025 | -$34.5M | -$7.5M |
| Q1 2025 | -$39.1M | -$9.1M |
| Q4 2024 | -$28.3M | -$4.1M |
TCRX has burned cash in almost every quarter: −$112M over the past year, against −$136M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TCRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +77.1K shares |
| 1 year | +0.1% | +190K shares |
| 3 years | +175% | +82.8M shares |
| 5 years | +443% | +106M shares |
TCRX has 130M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TCRX Net Leverage
TCRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.3 | Oversold |
| Stochastic | 1.3 | Oversold |
TCRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TCRX PE vs Healthcare Sector
TCRX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TCRX on trend strength, trading above more of its moving averages.
TCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.23 | 26% below |
| 20 week MA | $0.53 | 68% below |
| 50 week MA | $0.85 | 80% below |
| 100 week MA | $1.34 | 87% below |
| 200 week MA | $3.02 | 94% below |
TCRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TCRX on returns for 2026, with the stronger performance.
TCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.5 | $4.86 | -54% |
| 2022 | $4.86 | $1.51 | -69% |
| 2023 | $1.51 | $5.83 | +286% |
| 2024 | $5.83 | $3.06 | -48% |
| 2025 | $3.06 | $1.06 | -65% |
| 2026 YTD | $1.06 | $0.17 | -84% |
TCRX's yearly returns have swung widely, from +286% in 2023 to −69% in 2022. It's down 84% so far in 2026.